放疗前诱导免疫治疗在不可切除Ⅲ期非小细胞肺癌中的研究进展
Research progress of induction immunotherapy before radiotherapy in unresectable stage Ⅲ non-small cell lung cancer
曾丽 1张洪攀 1马代远1
作者信息
- 1. 川北医学院,川北医学院附属医院肿瘤科(四川省南充市 637000)
- 折叠
摘要
肺癌是全世界癌症相关死亡的主要原因,其中以非小细胞肺癌(non-small cell lung cancer,NSCLC)最为常见.临床中超过 1/3的NSCLC患者在初诊时已处于Ⅲ期,且其中大部分不可切除.放化疗(chemoradiotherapy,CRT)为不可切除Ⅲ期NSCLC的标准治疗方案,然而疗效较差.随着免疫检查点抑制剂的出现,CRT后的巩固免疫治疗使得不可切除Ⅲ期NSCLC患者的生存率较单纯CRT显著提升,但仍有部分患者未能从巩固免疫治疗中获益.目前,基于诱导免疫治疗在可切除Ⅲ期NSCLC中取得的显著效果,探索诱导免疫治疗在不可切除Ⅲ期NSCLC的研究已展开.本文就放疗前的诱导免疫治疗在不可切除Ⅲ期NSCLC的作用机制、最新临床研究进展和诱导免疫治疗周期进行综述,以期为不可切除Ⅲ期NSCLC的临床治疗提供参考依据.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide,and non-small cell lung cancer(NSCLC)is the most common type.Because more than one-third of NSCLC patients are diagnosed at stage Ⅲ,most of these tumors are unresectable.Chemoradiother-apy(CRT)is the standard treatment for unresectable stage Ⅲ NSCLC;however,its curative efficacy is poor.Compared with simple CRT,the survival rate of patients with unresectable stage Ⅲ NSCLC following consolidated immunotherapy after CRT has significantly improved ow-ing to the emergence of immune checkpoint inhibitors.However,a subset of patients do not benefit from consolidated immunotherapy.Based on the effectiveness of induction immunotherapy in resectable stage Ⅲ NSCLC,studies have been conducted to extend its application in unresectable stage Ⅲ NSCLC.This article reviews the mechanism of action,recent advancements in clinical research,and cycle of induc-tion immunotherapy before radiotherapy in unresectable stage Ⅲ NSCLC to provide a reference for clinical treatment of unresectable stageⅢ NSCLC.
关键词
诱导免疫治疗/非小细胞肺癌/研究进展Key words
induction immunotherapy/non-small cell lung cancer(NSCLC)/research progress引用本文复制引用
基金项目
四川省自然科学基金(2023NSFSC0730)
川北医学院附属医院项目(2022JB005)
华通国康医学研究专项(2023HT072)
出版年
2024
NETL
NSTL
万方数据